Although the myocardium contains progenitor cells potentially capable of regenerating tissue upon lethal ischaemic injury, their actual role in post-infarction heart healing is negligible. Therefore, transplantation of extra-cardiac stem cells is a promising therapeutic approach for post-infarction heart dysfunction. Paracrine cardiotropic factors released by the grafted cells, such as the cardiotropic hormone relaxin (RLX), may beneficially influence remodelling of recipient hearts. The current study was designed to address whether grafting of mouse C2C12 myoblasts, genetically engineered to express green fluorescent protein (C2C12/GFP) or GFP and RLX (C2C12/RLX), are capable of improving long-term heart remodelling in a rat model of surgically induced chronic myocardial infarction. One month after myocardial infarction, rats were treated with either culture medium (controls), or C2C12/GFP cells, or C2C12/RLX cells plus exogenous RLX, or exogenous RLX alone. The therapeutic effects were monitored for 2 further months. Cell transplantation and exogenous RLX improved the main echocardiographic parameters of cardiac function, increased myocardial viability (assessed by positron emission tomography), decreased cardiac sclerosis and myocardial cell apoptosis and increased microvascular density in the post-infarction scar tissue. These effects were maximal upon treatment with C2C12/RLX plus exogenous RLX. These functional and histopathological findings provide further experimental evidence that myoblast cell grafting can improve myocardial performance and survival during post-infarction heart remodelling and dysfunction. Further, this study provides a proof-of-principle to the novel concept that genetically engineered grafted cells can be effectively employed as cell-based vehicles for the local delivery of therapeutic cardiotropic substances, such as RLX, capable of improving adverse heart remodelling. PMID: 18798866 [PubMed - indexed for MEDLINE]

Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy*. * Bonacchi and Nistri contributed equally to this article / M. Bonacchi; S. Nistri; C. Nanni; S. Gelsomino; A. Pini; L. Cinci; M. Maiani; S. Zecchi-Orlandini; R. Lorusso; S. Fanti; J. Silvertown; D. Bani.. - In: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. - ISSN 1582-1838. - STAMPA. - 13:(2009), pp. 3437-3448. [10.1111/j.1582-4934.2008.00503.x]

Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy*. * Bonacchi and Nistri contributed equally to this article

BONACCHI, MASSIMO;NISTRI, SILVIA;PINI, ALESSANDRO;CINCI, LORENZO;MAIANI, MASSIMO;ZECCHI, SANDRA;BANI, DANIELE
2009

Abstract

Although the myocardium contains progenitor cells potentially capable of regenerating tissue upon lethal ischaemic injury, their actual role in post-infarction heart healing is negligible. Therefore, transplantation of extra-cardiac stem cells is a promising therapeutic approach for post-infarction heart dysfunction. Paracrine cardiotropic factors released by the grafted cells, such as the cardiotropic hormone relaxin (RLX), may beneficially influence remodelling of recipient hearts. The current study was designed to address whether grafting of mouse C2C12 myoblasts, genetically engineered to express green fluorescent protein (C2C12/GFP) or GFP and RLX (C2C12/RLX), are capable of improving long-term heart remodelling in a rat model of surgically induced chronic myocardial infarction. One month after myocardial infarction, rats were treated with either culture medium (controls), or C2C12/GFP cells, or C2C12/RLX cells plus exogenous RLX, or exogenous RLX alone. The therapeutic effects were monitored for 2 further months. Cell transplantation and exogenous RLX improved the main echocardiographic parameters of cardiac function, increased myocardial viability (assessed by positron emission tomography), decreased cardiac sclerosis and myocardial cell apoptosis and increased microvascular density in the post-infarction scar tissue. These effects were maximal upon treatment with C2C12/RLX plus exogenous RLX. These functional and histopathological findings provide further experimental evidence that myoblast cell grafting can improve myocardial performance and survival during post-infarction heart remodelling and dysfunction. Further, this study provides a proof-of-principle to the novel concept that genetically engineered grafted cells can be effectively employed as cell-based vehicles for the local delivery of therapeutic cardiotropic substances, such as RLX, capable of improving adverse heart remodelling. PMID: 18798866 [PubMed - indexed for MEDLINE]
2009
13
3437
3448
Goal 3: Good health and well-being for people
M. Bonacchi; S. Nistri; C. Nanni; S. Gelsomino; A. Pini; L. Cinci; M. Maiani; S. Zecchi-Orlandini; R. Lorusso; S. Fanti; J. Silvertown; D. Bani.
File in questo prodotto:
File Dimensione Formato  
Bonacchi_et_al-2009-Journal_of_Cellular_and_Molecular_Medicine.pdf

accesso aperto

Descrizione: Full Text
Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/388127
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 27
social impact